DAWN News and Press, Day One Biopharmaceuticals Inc. From 04/20/23

2023-04-20 09:00:52 ET Augmedix ( AUGX ) +91% a nnounces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation. United Insurance Holdings  ( UIHC ) +32% . CNS Pharmaceuticals ( CNSP ) +28% . MDxHealth...

BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster prese...

2023-04-07 07:37:15 ET Summary Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial years. However, the very large institutional presence with low-cost early shares and possibly early ...

2023-03-06 17:17:28 ET Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): FY GAAP EPS of -$2.17 beats by $0.01 . Cash, cash equivalents and short-term investments totaled $342.3 million on December 31, 2022. Based on Day One’s current operating plan, man...

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meanin...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management wil...

Day One Biopharmaceuticals ( NASDAQ: DAWN ) reported data from an ongoing phase 2 trial of tovorafenib to treat recurrent or progressive pediatric low-grade glioma (pLGG). The main goal of the study, dubbed FIREFLY-1, is overall response rate (ORR) and the company is eva...

Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patients Median duration of 8.4 months on therapy as of September 28, 2022, with 77% of patients remaining on treatment Additional data to be presented at a medical...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jerem...

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that man...